Danaher to buy antibody supplier Abcam for $5.7B
Bio Pharma Dive
AUGUST 28, 2023
The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.
Global Research Antibodies and Reagents Market Forecasts, 2020-2027: Focus on Antibodies, Production, Source, Research Area, Reagents, ELISA, Western Blot – ResearchAndMarkets.com
BioTech 365
JANUARY 4, 2021
Global Research Antibodies and Reagents Market Forecasts, 2020-2027: Focus on Antibodies, Production, Source, Research Area, Reagents, ELISA, Western Blot – ResearchAndMarkets.com Global Research Antibodies and Reagents Market Forecasts, 2020-2027: Focus on Antibodies, Production, Source, Research Area, Reagents, ELISA, Western Blot … Continue (..)
Reagent 
40
40 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
BioTech 365
SEPTEMBER 17, 2021
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend WALTHAM, Mass.–(BUSINESS –(BUSINESS WIRE)–PerkinElmer, Inc.
Reagent 52
52 
Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research
BioTech 365
MAY 10, 2021
Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Antibodies generated by Flow Eighteen38 to be used as research tools by Hubrecht Institute.
Reagent 52
52 
Global Research Antibodies and Reagents Market 2021-2030 with Becton Dickinson and Company, Thermo Fisher Scientific, Bio-Rad Laboratories and F. Hoffmann La-Roche Dominating – ResearchAndMarkets.com
BioTech 365
JANUARY 12, 2022
Global Research Antibodies and Reagents Market 2021-2030 with Becton Dickinson and Company, Thermo Fisher Scientific, Bio-Rad Laboratories and F.
Reagent 40
40 
Global Research Antibodies and Reagents Market Report 2020-2030: COVID-19 Growth and Change – Market is Expected to Stabilize and Reach $13.19 Billion in 2023 – ResearchAndMarkets.com
BioTech 365
DECEMBER 30, 2020
Global Research Antibodies and Reagents Market Report 2020-2030: COVID-19 Growth and Change – Market is Expected to Stabilize and Reach $13.19
Reagent 40
40 
Global Antinuclear Antibody Testing Market Report 2020: Market to Reach $2.4 Billion by 2027 – Assay Kits & Reagents Expected to Account for $1.2 Billion – ResearchAndMarkets.com
BioTech 365
DECEMBER 21, 2020
Global Antinuclear Antibody Testing Market Report 2020: Market to Reach $2.4 Billion by 2027 – Assay Kits & Reagents Expected to Account for $1.2 Billion – ResearchAndMarkets.com Global Antinuclear Antibody Testing Market Report 2020: Market to Reach $2.4 Billion by … Continue reading →
Reagent 40
40 
Sponsored content: Why choose Bethyl antibodies for your R&D
Drug Discovery World
JANUARY 10, 2023
For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.
Antibody 52
52 
LSBio Acquires Absolute Antibody Ltd.
BioTech 365
DECEMBER 22, 2020
LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.
Antibody 52
52 
£7M financing to drive commercialisation in cell and gene therapy
Drug Discovery World
FEBRUARY 21, 2024
MIP Discovery’s non-biological affinity reagents support a new approach to viral vector characterisation, viral vector purification, and safety and QC processes, such as the detection and removal of impurities. The funds will also support recruitment efforts to expand in-house CGT expertise.
Gene Therapy 52
52 
PerkinElmer to acquire antibody and reagent company BioLegend for $5bn
BioPharma Reporter
JULY 26, 2021
PerkinElmer will make the largest transaction in its history with the acquisition of Californiaâs BioLegend for $5.25bn.
Reagent 52
52 
The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies
BioTech 365
OCTOBER 7, 2020
Ten new monoclonal antibodies recognise distinct Spike protein epitopes on SARS-CoV-2 Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein Different epitopes support identification of matched-pair reagents for immunoassay development OXFORD, England–(BUSINESS WIRE)–The Native … (..)
Antibody 52
52 
Breakthrough ‘nanobody’ technology boosts thrombosis research
Drug Discovery World
OCTOBER 18, 2023
The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody fragments called nanobodies and crosslinked these to make ligands to four platelet receptors (GPVI, CLEC-2, FcɣRIIA and PEAR1). Reagents based on nanobodies will increase our understanding of platelet activation in the laboratory.
Research 52
52 
The ABCs of Transitioning PK Assays from Preclinical to Clinical
Worldwide Clinical Trials
SEPTEMBER 29, 2022
For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.), a typical format is: receptor/target as capture with a generic binding reagent as detection (e.g., anti-human IgG).
Reagent 130
130 
Turning science into business: An optimised alternative to antibodies
Drug Discovery World
APRIL 3, 2023
I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies? DS: How are aptamers currently used in the development of precision treatments?
Antibody 52
52 
The latest drug discovery product launches
Drug Discovery World
MAY 25, 2023
The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos. Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.
Production 52
52 
Danaher to acquire Abcam
Drug Discovery World
AUGUST 30, 2023
Founded in 1998 and headquartered in Cambridge, UK, Abcam provides antibodies, reagents, biomarkers and assays for drug discovery, life sciences research, and diagnostics. The transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors.
Life Science 52
52 
LabCorp’s Innovative High-Speed COVID-19 Test Gets Emergency Use Authorization from the FDA
XTalks
OCTOBER 7, 2020
The innovative heat extraction process, which has sensitivity comparable to current extraction methods, captures viral particles directly, thereby eliminating the need for RNA extraction reagents to extract and concentrate viral RNA. This will help reduce both the materials and time required to complete molecular COVID-19 tests.
Reagent 98
98 
A new era in diagnostics: The growing demand for POC testing
Pharmaceutical Technology
SEPTEMBER 1, 2022
While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.
Manufacturing 130
130 
Transforming Biomanufacturing: Potential of Cell Free Systems
Roots Analysis
AUGUST 15, 2023
Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.
Protein 52
52 
BenchSci raises $50m to grow AI-powered R&D platform
pharmaphorum
JANUARY 25, 2022
The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.
Life Science 52
52 
Validated antibodies for rare cell and circulating tumour cell enumeration
Drug Discovery World
MARCH 28, 2024
Bio-Rad Laboratories has launched validated antibodies for rare cell and circulating tumour cell (CTC) enumeration for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits.
Antibody 52
52 
Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences
The Pharma Data
JANUARY 24, 2021
Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. .” Chris Bond , Ph.D., Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.
Engineer 52
52 
Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility
The Pharma Data
OCTOBER 14, 2020
15, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. MINNEAPOLIS , Oct. ” About Bio-Techne Corporation (NASDAQ: TECH).
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
The Pharma Data
MARCH 13, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE).
Drugs 52
52 
Rapid and high throughput Octet BLI applications in early monoclonal antibody discovery
Drug Discovery World
AUGUST 22, 2022
Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics.
Antibody 52
52 
Webinar: Applications in early monoclonal antibody discovery
Drug Discovery World
AUGUST 22, 2022
Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics.
Antibody 52
52 
Webinar – applications in early monoclonal antibody discovery
Drug Discovery World
AUGUST 30, 2022
In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. To secure your place, register for FREE now.
Antibody 52
52 
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
“For each production process, you have to generate the plasmids in huge quantities with GMP quality and then do a transient transfection, meaning you mix them with a transfection reagent and add that to the cells in a very controlled way,” explains Faust. For example, researchers have developed a two-plasmid cotransfection system.
Genome 244
244 
Webinar – Octet Bio-Layer Interferometry for antibody discovery
Drug Discovery World
SEPTEMBER 20, 2022
In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. To secure your place, register for FREE now.
Antibody 52
52 
Reflecting on ELRIG’s Drug Discovery 2022
Drug Discovery World
OCTOBER 13, 2022
There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .
Drugs 52
52 
Biden Warns of 500,000 COVID Deaths by February
The Pharma Data
JANUARY 22, 2021
The Biden team said it had identified 12 “immediate supply shortfalls” that have been critical to the pandemic response, including N95 surgical masks and isolation gowns, as well as swabs, reagents and pipettes used in testing, the Times reported. “We saw a knockout,” Moore said. “It was a scary result.”
Vaccination 52
52 
Fortis Life Sciences leads the way in custom antibody discovery
Drug Discovery World
DECEMBER 13, 2023
In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.
Life Science 59
59 
TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. All antibody titres were low. About TAKHZYRO ® (lanadelumab).
Allergies 52
52 
IN FOCUS: Syngene International
Pharmaceutical Technology
APRIL 28, 2023
Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.
Manufacturing 130
130 
Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
BioTech 365
OCTOBER 20, 2020
CHICAGO & MUNICH–(BUSINESS WIRE)–#Antibodies–Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. … Continue reading →
Antibody 52
52 
Biopharma Update on the Novel Coronavirus: October 20
The Pharma Data
OCTOBER 19, 2020
Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Diagnostics.
Vaccination 52
52 
Leveraging flow cytometry in drug discovery
Drug Discovery World
OCTOBER 21, 2022
Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . Best antibody development practices are summarised in Fig. Overview, evolution, trends .
Reagent 52
52 
Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials
XTalks
APRIL 22, 2022
Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.
Reflecting on PEGS Europe 2023
Drug Discovery World
NOVEMBER 30, 2023
The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents.
Antibody 59
59 
Roche working “around the clock” to tackle UK test supply problems
pharmaphorum
OCTOBER 7, 2020
The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new warehouse, which ironically is intended to make production quicker and more efficient through the use of automated processes. Antibody test order.
Antibody 72
72 
Cell analysis system could streamline cell and gene therapy manufacturing
Drug Discovery World
SEPTEMBER 28, 2022
To further streamline the customer experience, optimised reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also part of the solution. .
Gene Therapy 52
52 
The importance of glycan analysis and characterisation for biopharma
Drug Discovery World
OCTOBER 12, 2022
Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.
Protein 52
52 
BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
The Pharma Data
DECEMBER 2, 2020
ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.
Drugs 52
52 
Let's personalize your content